Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm

被引:8
|
作者
Nishino, Mizuki [1 ,2 ]
Wakai, Satoshi [3 ]
Hida, Tomoyuki [1 ,2 ]
Dahlberg, Suzanne E. [4 ]
Ozaki, Masahiro [3 ]
Hatabu, Hiroto [1 ,2 ]
Tachizaki, Hisashi [3 ]
Johnson, Bruce E. [5 ,6 ,7 ]
机构
[1] Brigham & Womens Hosp, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[3] Canon Med Syst Corp, 1385 Shimoishigami, Otawara, Tochigi 3248550, Japan
[4] Dana Farber Canc Inst, Dept Biostat, 450 Brookline Ave, Boston, MA 02215 USA
[5] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
[6] Dana Farber Canc Inst, Dept Med, 450 Brookline Ave, Boston, MA 02215 USA
[7] Brigham & Womens Hosp, 450 Brookline Ave, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
Lung cancer; Epidermal growth factor receptor; EGFR inhibitor; Computed tomography; Tumor growth rate; DIFFERENT TREATMENT MODALITIES; RESPONSE EVALUATION CRITERIA; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; NSCLC PATIENTS; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; GEFITINIB; PROGRESSION;
D O I
10.1016/j.ejrad.2018.10.014
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To develop an automated analytic module for calculation of tumor growth rate from serial CT scans and to apply the module and evaluate reproducibility in a pilot cohort of advanced NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors. Materials and methods: The module utilized a commercially available image-processing workstation equipped with a validated tumor volume measurement tool. An automated analytic software module was programmed with the capability to record and display serial tumor volume changes and to calculate tumor volume growth rate over time and added to the workstation. The module was applied to evaluate the tumor growth rate in a pilot cohort of 24 EGFR-mutant patients treated with EGFR inhibitors, and reproducibility references as tested by two independent thoracic radiologists. Results: The module analyzed chest CT scans from 24 patients (5 males, 19 females; median age: 61) with a median of 8 scans per patient, totaling 227 scans and provided a graphical display with an automated and instant calculation of tumor growth rate after the nadir volume for each patient. High inter and intraobserver agreements were noted for tumor growth rates, with concordance correlation coefficients of 0.9323 and 0.9668, respectively. Interpretation of slow versus fast tumor growth using previously identified threshold of <= 0.15/month had a perfect interobserver agreement (kappa = 1.00), and an excellent intraobserver agreement (kappa = 0.895). Conclusions: The present study describes the development of an image analytic module for assessing tumor growth rate and the data demonstrates the functionality and reproducibility of the module in a pilot cohort of EGFR-mutant NSCLC patients treated with EGFR-TKI. The image analytic module is an initial step for clinical translation of the tumor growth rate approach to guide cancer treatment in precision oncology.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 50 条
  • [31] Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
    Inomata, Minehiko
    Matsumoto, Masahiro
    Mizushima, Isami
    Hayashi, Kana
    Seto, Zenta
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Hayashi, Ryuji
    Matsui, Shoko
    Tobe, Kazuyuki
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2022, 16 (01)
  • [32] Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
    Wang, Haiyang
    Yu, Xiaoqing
    Fan, Yun
    Jiang, Youhua
    ONCOTARGETS AND THERAPY, 2018, 11 : 2149 - 2155
  • [33] Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer
    Kim, Tae-Jung
    Hong, Soon Auck
    Kim, Okran
    Kim, Seung Joon
    Yang, Ji-Hyun
    Joung, Eun Kyo
    Kang, Jin-Hyoung
    Hong, Sook-Hee
    ONCOTARGET, 2017, 8 (64) : 107630 - 107639
  • [34] EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
    Ke, E-E
    Wu, Yi-Long
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (11) : 887 - 903
  • [35] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Chmielecki, Juliann
    Foo, Jasmine
    Oxnard, Geoffrey R.
    Hutchinson, Katherine
    Ohashi, Kadoaki
    Somwar, Romel
    Wang, Lu
    Amato, Katherine R.
    Arcila, Maria
    Sos, Martin L.
    Socci, Nicholas D.
    Viale, Agnes
    de Stanchina, Elisa
    Ginsberg, Michelle S.
    Thomas, Roman K.
    Kris, Mark G.
    Inoue, Akira
    Ladanyi, Marc
    Miller, Vincent A.
    Michor, Franziska
    Pao, William
    SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
  • [36] Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer
    Kawamura, Takahisa
    Kenmotsu, Hirotsugu
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Omae, Katsuhiro
    Mori, Keita
    Tanigawara, Yusuke
    Nakajima, Takashi
    Ohde, Yasuhisa
    Endo, Masahiro
    Takahashi, Toshiaki
    CLINICAL LUNG CANCER, 2018, 19 (02) : E247 - E252
  • [37] Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
    Aboubakar Nana, Frank
    Ocak, Sebahat
    PHARMACEUTICS, 2021, 13 (09)
  • [38] PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
    Ferrara, Miriam Grazia
    Martini, Maurizio
    D'Argento, Ettore
    Forcella, Chiara
    Vita, Emanuele
    Di Noia, Vincenzo
    Sperduti, Isabella
    Bilotta, Mirna
    Ribelli, Marta
    Damiano, Paola
    Cannella, Antonella
    Stefani, Alessio
    Pilotto, Sara
    Carbone, Carmine
    Piro, Geny
    Milella, Michele
    Tortora, Giampaolo
    Bria, Emilio
    CLINICAL LUNG CANCER, 2021, 22 (04) : 351 - 360
  • [39] Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer
    Rossi, Sabrina
    Finocchiaro, Giovanna
    Di Noia, Vincenzo
    Bonomi, Maria
    Cerchiaro, Eleonora
    De Rose, Fiorenza
    Franceschini, Davide
    Navarria, Pierina
    Ceresoli, Giovanni Luca
    Beretta, Giordano Domenico
    D'Argento, Ettore
    Scorsetti, Marta
    Santoro, Armando
    Toschi, Luca
    FUTURE ONCOLOGY, 2019, 15 (33) : 3775 - 3782
  • [40] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    CANCERS, 2019, 11 (09)